中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
11期
1468-1469
,共2页
赵超%牟善玲%张玉海%王云
趙超%牟善玲%張玉海%王雲
조초%모선령%장옥해%왕운
颅脑损伤%依达拉奉%地诺前列素
顱腦損傷%依達拉奉%地諾前列素
로뇌손상%의체랍봉%지낙전렬소
Craniocerebral trauma%Edaravone%Dinoprost
目的 探讨依达拉奉对重度颅脑外伤(SHI)患者预后及血浆8-表氧前列腺素F2α(8-iso-PGF2α)水平的影响.方法 68例SHI患者在知情同意情况下,按入院序号随机均分为治疗组和对照组各34例,两组均给予常规治疗,治疗组在此基础上加用依达拉奉注射液治疗,治疗14 d.观察比较两组血浆8-iso-PGF2α水平、格拉斯哥昏迷评分(GCS)及预后分级评分(GOS)等情况.结果 治疗组治疗第7、14、30天时,治疗组血浆8-iso-PGFF2α水平分别为(18.84±3.96)、(14.21±3.67)、(12.98±4.03)ng/L,显著低于对照组的(25.53±4.01)、(21.08±3.40)、(16.64±3.78)ng/L(t=7.56、6.98、8.54,均P＜0.05).治疗组治疗前、治疗14 d后GCS评分分别为(4.49±1,21)分、(12.34±2.47)分,对照组分别为(4.36 ±1.13)分、(10.45±1.65)分,两组治疗14 d后GCS评分与其治疗前差异均有统计学意义(t=6.43、7.21,均P＜0.05),两组治疗14 d后GCS评分差异有统计学意义(t=7.44,P＜0.05);治疗组3个月GOS评分为(4.76±1.54)分,明显高于对照组的(3.51±1.33)分(t=5.32,P＜0.05).治疗3个月后,治疗组良好16例、中残6例、重残4例、植物生存3例、死亡5例,对照组分别为9例、7例、5例、2例、11例,两组临床疗效差异有统计学意义(μ=11.21,P＜0.05).结论 应用依达拉奉可显著降低颅脑外伤患者血浆8-iso-PGF2α水平,改善患者预后.
目的 探討依達拉奉對重度顱腦外傷(SHI)患者預後及血漿8-錶氧前列腺素F2α(8-iso-PGF2α)水平的影響.方法 68例SHI患者在知情同意情況下,按入院序號隨機均分為治療組和對照組各34例,兩組均給予常規治療,治療組在此基礎上加用依達拉奉註射液治療,治療14 d.觀察比較兩組血漿8-iso-PGF2α水平、格拉斯哥昏迷評分(GCS)及預後分級評分(GOS)等情況.結果 治療組治療第7、14、30天時,治療組血漿8-iso-PGFF2α水平分彆為(18.84±3.96)、(14.21±3.67)、(12.98±4.03)ng/L,顯著低于對照組的(25.53±4.01)、(21.08±3.40)、(16.64±3.78)ng/L(t=7.56、6.98、8.54,均P＜0.05).治療組治療前、治療14 d後GCS評分分彆為(4.49±1,21)分、(12.34±2.47)分,對照組分彆為(4.36 ±1.13)分、(10.45±1.65)分,兩組治療14 d後GCS評分與其治療前差異均有統計學意義(t=6.43、7.21,均P＜0.05),兩組治療14 d後GCS評分差異有統計學意義(t=7.44,P＜0.05);治療組3箇月GOS評分為(4.76±1.54)分,明顯高于對照組的(3.51±1.33)分(t=5.32,P＜0.05).治療3箇月後,治療組良好16例、中殘6例、重殘4例、植物生存3例、死亡5例,對照組分彆為9例、7例、5例、2例、11例,兩組臨床療效差異有統計學意義(μ=11.21,P＜0.05).結論 應用依達拉奉可顯著降低顱腦外傷患者血漿8-iso-PGF2α水平,改善患者預後.
목적 탐토의체랍봉대중도로뇌외상(SHI)환자예후급혈장8-표양전렬선소F2α(8-iso-PGF2α)수평적영향.방법 68례SHI환자재지정동의정황하,안입원서호수궤균분위치료조화대조조각34례,량조균급여상규치료,치료조재차기출상가용의체랍봉주사액치료,치료14 d.관찰비교량조혈장8-iso-PGF2α수평、격랍사가혼미평분(GCS)급예후분급평분(GOS)등정황.결과 치료조치료제7、14、30천시,치료조혈장8-iso-PGFF2α수평분별위(18.84±3.96)、(14.21±3.67)、(12.98±4.03)ng/L,현저저우대조조적(25.53±4.01)、(21.08±3.40)、(16.64±3.78)ng/L(t=7.56、6.98、8.54,균P＜0.05).치료조치료전、치료14 d후GCS평분분별위(4.49±1,21)분、(12.34±2.47)분,대조조분별위(4.36 ±1.13)분、(10.45±1.65)분,량조치료14 d후GCS평분여기치료전차이균유통계학의의(t=6.43、7.21,균P＜0.05),량조치료14 d후GCS평분차이유통계학의의(t=7.44,P＜0.05);치료조3개월GOS평분위(4.76±1.54)분,명현고우대조조적(3.51±1.33)분(t=5.32,P＜0.05).치료3개월후,치료조량호16례、중잔6례、중잔4례、식물생존3례、사망5례,대조조분별위9례、7례、5례、2례、11례,량조림상료효차이유통계학의의(μ=11.21,P＜0.05).결론 응용의체랍봉가현저강저로뇌외상환자혈장8-iso-PGF2α수평,개선환자예후.
Objective To explore the effect of edaravone on serum level of 8-iso-PGF2α and prognosis in patients with severe head injury(SHI).Methods 68 patients with SHI were randomly divided into two groups,which were both given conventional treatment,while the treatment group was also given extra injection of edaravone for 14d.8-iso-PGF2α,GCS score and GOS were observed and compared between the two groups respectively.Results The decrease of serum level of 8-iso-PGF2α in treatment group was significantly higher than that of the control group,the GCS score and good outcomes after 3 months was significantly higher than that of the control group after the treatment(P＜0.05).Conclusion Edaravone could reduce the serum level of 8-iso-PGF2α in SHI patients and improve the prognosis.which was woah clinical application.
